9VGR
Crystal Structure of the NUAK1-MARK3 kinase domain chimera bound with small molecule inhibitor 4-((5-((5-chloro-4-(((3R,3aR,6R,6aR)-6-methoxyhexahydrofuro[3,2-b]furan-3-yl)oxy)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)carbamoyl)-1-methyl-3H-pyrazol-1-ium-3-ide
This is a non-PDB format compatible entry.
Summary for 9VGR
| Entry DOI | 10.2210/pdb9vgr/pdb |
| Descriptor | MAP/microtubule affinity-regulating kinase 3, N-[5-[[4-[[(3R,3aR,6R,6aR)-3-methoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl]oxy]-5-chloranyl-pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methyl-amino]phenyl]-1-methyl-pyrazole-4-carboxamide (3 entities in total) |
| Functional Keywords | kinase, cytosolic protein |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 1 |
| Total formula weight | 38331.73 |
| Authors | |
| Primary citation | Li, S.,Wang, Y.,Liu, X.,Zhang, H.,Lei, C.,Wang, Z.,Zhang, Y.,Du, X.,Xu, L.,Li, Z.,Shi, Y.,Ning, X.,Cao, J.,Zhang, Z.M.,Ma, D.,Ding, K. Structure-Based Design of Potent and Highly Selective NUAK1 Inhibitors by Exploiting a Unique Glutamate Switch for the Prevention of Tumor Growth, Migration, and Invasion. J.Med.Chem., 69:7817-7838, 2026 Cited by PubMed Abstract: NUAK1, an AMPK-related kinase overexpressed in cancers, plays a crucial role in tumor metastasis and cell survival, making it an attractive cancer therapeutic target. Herein, we report potent, selective NUAK1 inhibitors via structure-guided repurposing of a covalent JAK3 inhibitor. By capitalizing on the critical structural difference─Cys909 in JAK3 versus Glu139 in NUAK1─we substituted the electrophilic warhead with glutamate-favoring moieties, a modification that confers selective NUAK1 targeting. Supporting this design rationale, cocrystal structures verify the specific engagement of these moieties with the Glu139 residue of NUAK1. Among the synthesized analogs, candidate compound exhibits subnanomolar NUAK1 inhibition (IC = 0.49 nM) and kinome-wide selectivity. Besides, suppresses proliferation, migration, and invasion of triple-negative breast cancer cells, reverses EMT markers, and shows robust antitumor efficacy in mouse xenografts. This study provides a promising lead and validates Glu139 as an anchor for selective NUAK1 targeting. PubMed: 41855469DOI: 10.1021/acs.jmedchem.5c03079 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.00000662781 Å) |
Structure validation
Download full validation report






